China Pharma (CPHI)
China Pharma Earnings Yield: 108.6%
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
CPHI Earnings Yield Rankings
| Overall | 99th percentile | 16 of 4312 |
| Sector | 99th percentile | 3 of 492 in Healthcare |
| Industry | 96th percentile | 1 of 25 in Drug Manufacturers - Major |
CPHI Earnings Yield Range, Past 5 Years
| Minimum | 11.15% | Dec 2007 |
| Maximum | 108.6% | May 25 2012 |
| Average | 29.69% |
About Earnings Yield
Earnings yield is earnings per share from the previous four quarters divided by the share price. It is the reciprocal of the P/E ratio. The earnings yield is quoted as a percentage, which illustrates the percentage of each dollar invested that was earned by the company during the past twelve months.
The earnings yield can be used to compare the earnings of a stock, sector or the whole market against bond yields. Generally, the earnings yields of equities are higher than the yield of risk-free treasury bonds. Financial theorists argue that this difference exists because stock earnings are riskier than bond coupon payments.
If a company has an earnings yield of 64%, investors are purchasing $0.64 of earnings per dollar invested.
Learn More
You may also be interested in these CPHI related companies
CPHI News
Top 4 Small-Cap Stocks In The Drug Manufacturers-Major Industry With The Highest Profit Margin
May 23, 2:27AM Benzinga
May 23, 2:27AM Benzinga
Shares of China Pharma Holdings (CPHI) trading halted on circuit breaker, shares down 12%
May 17, 12:29PM Street Insider
May 17, 12:29PM Street Insider
China Pharma Holdings, Inc. to Report First Quarter of Fiscal Year 2012 Financial Results on May 15, 2012
May 04, 8:00AM PR Newswire
May 04, 8:00AM PR Newswire
China Pharma Holdings, Inc. to Report Fiscal Year 2011 Financial Results on March 15, 2012
Mar 06, 6:00PM PR Newswire
Mar 06, 6:00PM PR Newswire
Top 4 Small-Cap Stocks In The Drug Manufacturers-Major Industry With The Highest Revenue
Mar 02, 2:59AM Benzinga
Mar 02, 2:59AM Benzinga
China Pharma Holdings, Inc. to Report Third Quarter 2011 Financial Results on November 11, 2011
Nov 07, 8:00AM PR Newswire
Nov 07, 8:00AM PR Newswire
I like the numbers of out $CPHI this morning ... $0.23 in H1 EPS, if extrapolated, puts this at < 5X PE. Adding to cheap china stocks
about 291 days ago by AGORACOM
about 291 days ago by AGORACOM
China Pharma Holdings, Inc. Reports Second Quarter 2011 Financial Results
Aug 11, 6:00AM PR Newswire
Aug 11, 6:00AM PR Newswire
China Pharma Holdings, Inc. to Report Second Quarter 2011 Financial Results on August 11, 2011
Aug 03, 8:00AM PR Newswire
Aug 03, 8:00AM PR Newswire
China Pharma Holdings, Inc. States It Knows of No Events That Could Have Caused Unusual Market Activity
Jun 16, 3:53PM PR Newswire
Jun 16, 3:53PM PR Newswire
$CPHI finally moved a little..should go next week should be support around that 100dma
about 668 days ago by swtrigger
about 668 days ago by swtrigger
Time to Invest in China? http://www.superstockblog.com/time-to-invest-in-china/ $CPHI
about 805 days ago by superstockblog
about 805 days ago by superstockblog
$CPHI looking like a "newer" speculative China play; drug maker at 7.6X earnings
about 908 days ago by OptionRadar
about 908 days ago by OptionRadar
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| CPHI | 0.3499 | -0.00 | -0.03% | 15.23M |
| CPHD | 38.47 | +0.38 | +1.00% | 2.519B |
| DLB | 43.96 | -0.04 | -0.09% | 4.777B |
| DLA | 14.17 | -0.03 | -0.21% | 119.74M |
| DL | 3.40 | -0.07 | -2.02% | 120.60M |
| DKA | 21.58 | -0.07 | -0.32% | |
| DK | 16.91 | +0.47 | +2.86% | 983.49M |
| DCOM | 13.34 | +0.04 | +0.30% | 469.17M |
| DCM | 15.83 | -0.05 | -0.31% | 65.64B |
| DCIX | 7.07 | -0.02 | -0.28% | 163.18M |
